Dbv Technologies ADR (DBVT) Stock Price, Quote & News - Mboum

Company Profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlie...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 1 55 42 78 78

Website: www.dbv-technologies.com

Address:

BAtiment IRO, 107 Av. de la REpublique, Châtillon, France

Mortimer2020 Apr. 8 at 2:10 PM

$DBVT where are we at with getting this thing to market

0 · Reply

focafoca99 Apr. 3 at 9:02 PM

$DBVT release the monthly share-count and voting-rights disclosure as of March 31.

0 · Reply

WallStreetBuyDip Apr. 3 at 6:13 PM

$DBVT Massive volume spike of 446,600 shares traded, well over 2x the average volume. Price staying around $21.06, with highs at $24.54 and lows at $6.50. Recent price action has been quite active with significant volume increases. Waiting for a lower H% before considering entry.

0 · Reply

RunnerSignals Apr. 3 at 1:27 PM

$VSAT $AAOI $AXTI $KURA $DBVT RSI flip = early money signal not extended yet, setups still developing https://stocksrunner.com/news/2026-04-03-momentum-rsi-breakout

0 · Reply

erevnon Mar. 27 at 2:54 PM

Citizens maintains DBV Technologies $DBVT at Market Outperform and raises the price target from $45 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

OfficialStocktwitsUser Mar. 26 at 12:23 PM

$DBVT RSI: 40.70, MACD: -0.4956 Vol: 1.38, MA20: 21.02, MA50: 21.42 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

OpenOutcrier Mar. 25 at 12:14 PM

$DBVT (+5.6% pre) DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review https://ooc.bz/l/97133

0 · Reply

thejaygatsby Mar. 24 at 2:14 PM

$DBVT earnings are today right?

0 · Reply

Zamboni18 Mar. 12 at 1:40 PM

0 · Reply

medguy Mar. 12 at 4:16 AM

Looking for bounce $DBVT

0 · Reply

Latest News on DBVT

DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

2026-04-02T20:34:00.000Z - 8 days ago

DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

Thu, 02 Apr 2026 16:30:00 -0400 - 8 days ago

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

DBV Technologies S.A.: DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

2026-03-26T21:34:00.000Z - 15 days ago

DBV Technologies S.A.: DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

DBV Technologies S.A.: DBV Technologies Reports Full Year 2025 Financial Results and Business Update

2026-03-26T21:22:00.000Z - 15 days ago

DBV Technologies S.A.: DBV Technologies Reports Full Year 2025 Financial Results and Business Update

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

Thu, 26 Mar 2026 17:19:00 -0400 - 15 days ago

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

DBV Technologies Reports Full Year 2025 Financial Results and Business Update

Thu, 26 Mar 2026 17:06:00 -0400 - 15 days ago

DBV Technologies Reports Full Year 2025 Financial Results and Business Update

DBV Technologies S.A.: DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

2026-03-24T20:34:00.000Z - 17 days ago

DBV Technologies S.A.: DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Tue, 24 Mar 2026 16:30:00 -0400 - 17 days ago

DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

DBV Technologies S.A.: DBV Technologies to Participate in Upcoming March Investor Conferences

2026-03-04T21:34:00.000Z - 5 weeks ago

DBV Technologies S.A.: DBV Technologies to Participate in Upcoming March Investor Conferences

DBV Technologies to Participate in Upcoming March Investor Conferences

Mar 4, 2026, 4:30 PM EST - 5 weeks ago

DBV Technologies to Participate in Upcoming March Investor Conferences

DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026

2026-03-03T21:34:00.000Z - 5 weeks ago

DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026

DBV Technologies Peanut Patch Meets Primary Endpoint In Phase 3 VITESSE Study

2026-03-02T11:16:31.000Z - 5 weeks ago

DBV Technologies Peanut Patch Meets Primary Endpoint In Phase 3 VITESSE Study

DBVT Shares Promising Phase 3 Trial Results for Viaskin Peanut

2026-03-01T16:52:03.000Z - 5 weeks ago

DBVT Shares Promising Phase 3 Trial Results for Viaskin Peanut

DBV Technologies S.A.: DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

2026-02-28T19:34:00.000Z - 5 weeks ago

DBV Technologies S.A.: DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

Feb 28, 2026, 2:25 PM EST - 5 weeks ago

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

Feb 10, 2026, 4:30 PM EST - 2 months ago

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

Feb 5, 2026, 4:30 PM EST - 2 months ago

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

Jan 16, 2026, 6:11 PM EST - 2 months ago

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

Jan 12, 2026, 4:00 PM EST - 3 months ago

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

Jan 5, 2026, 4:00 PM EST - 3 months ago

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

Dec 17, 2025, 8:49 AM EST - 4 months ago

Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

Nov 11, 2025, 11:50 PM EST - 5 months ago

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 4, 2025, 4:30 PM EST - 5 months ago

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

Nov 3, 2025, 4:30 PM EST - 5 months ago

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

Oct 30, 2025, 4:30 PM EDT - 5 months ago

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

Oct 30, 2025, 3:00 AM EDT - 5 months ago

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

Oct 29, 2025, 6:47 PM EDT - 5 months ago

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

DBV Technologies Announces Resignation of Board Member

Sep 18, 2025, 4:30 PM EDT - 7 months ago

DBV Technologies Announces Resignation of Board Member

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

Sep 5, 2025, 4:30 PM EDT - 7 months ago

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

Jul 29, 2025, 4:17 PM EDT - 9 months ago

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results

Jul 29, 2025, 4:08 PM EDT - 9 months ago

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Jul 28, 2025, 4:30 PM EDT - 9 months ago

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer

Jul 22, 2025, 4:30 PM EDT - 9 months ago

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

Jun 25, 2025, 4:15 PM EDT - 10 months ago

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

DBV Technologies to Participate in Upcoming EAACI Congress 2025

Jun 12, 2025, 4:05 PM EDT - 10 months ago

DBV Technologies to Participate in Upcoming EAACI Congress 2025

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

Jun 11, 2025, 4:30 PM EDT - 10 months ago

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

Jun 3, 2025, 4:30 PM EDT - 11 months ago

DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

Combined General Meeting of June 11, 2025

May 15, 2025, 4:30 PM EDT - 11 months ago

Combined General Meeting of June 11, 2025

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

May 5, 2025, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

DBV Technologies Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:00 PM EDT - 1 year ago

DBV Technologies Reports First Quarter 2025 Financial Results

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

Apr 11, 2025, 4:30 PM EDT - 1 year ago

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

DBV Technologies ADRs Rise After Up to $306.9M in New Financing

Mar 28, 2025, 11:09 AM EDT - 1 year ago

DBV Technologies ADRs Rise After Up to $306.9M in New Financing

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

Mar 27, 2025, 10:30 PM EDT - 1 year ago

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results

Mar 24, 2025, 2:30 AM EDT - 1 year ago

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

Feb 25, 2025, 4:01 PM EST - 1 year ago

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids

Dec 12, 2024, 9:59 AM EST - 1 year ago

DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

Dec 11, 2024, 4:05 PM EST - 1 year ago

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBV Technologies Announces Plan to Implement ADS Ratio Change

Nov 11, 2024, 4:30 PM EST - 1 year ago

DBV Technologies Announces Plan to Implement ADS Ratio Change

DBV Technologies Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:30 PM EST - 1 year ago

DBV Technologies Reports Third Quarter 2024 Financial Results

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

Oct 22, 2024, 4:45 PM EDT - 1 year ago

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

Oct 18, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

Sep 23, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report

Jul 30, 2024, 5:30 PM EDT - 1 year ago

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results

Jul 30, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024

Jul 29, 2024, 1:30 AM EDT - 1 year ago

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024

DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 4:30 PM EDT - 2 years ago

DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

DBV Technologies to Participate in Upcoming EAACI 2024 Congress

May 30, 2024, 4:30 PM EDT - 2 years ago

DBV Technologies to Participate in Upcoming EAACI 2024 Congress

DBV Technologies Announces Results of its 2024 Combined General Meeting

May 16, 2024, 4:30 PM EDT - 2 years ago

DBV Technologies Announces Results of its 2024 Combined General Meeting

Mortimer2020 Apr. 8 at 2:10 PM

$DBVT where are we at with getting this thing to market

0 · Reply

focafoca99 Apr. 3 at 9:02 PM

$DBVT release the monthly share-count and voting-rights disclosure as of March 31.

0 · Reply

WallStreetBuyDip Apr. 3 at 6:13 PM

$DBVT Massive volume spike of 446,600 shares traded, well over 2x the average volume. Price staying around $21.06, with highs at $24.54 and lows at $6.50. Recent price action has been quite active with significant volume increases. Waiting for a lower H% before considering entry.

0 · Reply

RunnerSignals Apr. 3 at 1:27 PM

$VSAT $AAOI $AXTI $KURA $DBVT RSI flip = early money signal not extended yet, setups still developing https://stocksrunner.com/news/2026-04-03-momentum-rsi-breakout

0 · Reply

erevnon Mar. 27 at 2:54 PM

Citizens maintains DBV Technologies $DBVT at Market Outperform and raises the price target from $45 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

OfficialStocktwitsUser Mar. 26 at 12:23 PM

$DBVT RSI: 40.70, MACD: -0.4956 Vol: 1.38, MA20: 21.02, MA50: 21.42 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

OpenOutcrier Mar. 25 at 12:14 PM

$DBVT (+5.6% pre) DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review https://ooc.bz/l/97133

0 · Reply

thejaygatsby Mar. 24 at 2:14 PM

$DBVT earnings are today right?

0 · Reply

Zamboni18 Mar. 12 at 1:40 PM

0 · Reply

medguy Mar. 12 at 4:16 AM

Looking for bounce $DBVT

0 · Reply

focafoca99 Mar. 3 at 10:47 PM

$DBVT dropped a voting-rights/share-count update.

0 · Reply

kriks2611 Mar. 2 at 9:56 PM

0 · Reply

notreload_ai Mar. 2 at 4:10 PM

$DBVT reveals new VITESSE Phase 3 data at AAAAI 2026: 83% of kids on VIASKIN Peanut Patch increased safe peanut dose vs 48% on placebo, with excellent safety. https://notreload.xyz/kids-tolerate-more-peanut-with-viaskin-patch-in-landmark-study/

0 · Reply

OpenOutcrier Mar. 2 at 1:37 PM

$DBVT (+1.4% pre) Phase 3 VITESSE data highlighted by DBV Technologies https://ooc.bz/l/95114

0 · Reply

AlertsAndNews Feb. 28 at 8:46 PM

$DBVT DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting "Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo group Approximately 60% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose by at least two doses at month 12, compared to 23% in the placebo group"

0 · Reply

Lalalilala Feb. 25 at 8:20 PM

$DBVT This is bad news, coming just two days before a Phase 3 data presentation. Run before it drops to $8 on Monday. 😩

0 · Reply

Lalalilala Feb. 24 at 8:59 PM

$DBVT up . Spéculation thursday expect 26$.

0 · Reply

BillionerOfKing Feb. 23 at 8:48 PM

$DBVT Current Stock Price: $21.14

1 · Reply

RodneyHammons200 Feb. 21 at 7:15 AM

$DBVT DBV Technologies develops allergy immunotherapy treatments. Clinical trial outcomes drive valuation. Funding risk remains significant.

0 · Reply

FadeChaser Feb. 18 at 9:17 AM

$DBVT Rare disease biotech where regulatory pathways define upside.

1 · Reply